GlassScriptPhysician profile
Dinesh Edem
NPI 1144575960
$1,714.46
in general payments reported to CMS, 2019-2025
15 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $188 · 2024: $590 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.65 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $761.60 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $204.31 | 2025 | Tavneos, Tepezza |
| Xeris Pharmaceuticals, INC. | $162.83 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $145.95 | 2024-2025 | Korlym |
| Abbvie INC. | $108.93 | 2025 | |
| Lilly USA, LLC | $75.62 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Kyowa Kirin, INC. | $44.48 | 2024-2025 | Crysvita |
| Dexcom, INC. | $44.41 | 2024-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $38.88 | 2024-2025 | Cequr Simplicity |
| Averitas Pharma INC. | $31.05 | 2024 | Qutenza |
| Neurocrine Biosciences, INC. | $25.37 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $18.93 | 2025 | Imcivree |
| Abbott Laboratories | $18.61 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.98 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $16.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinesh Edem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.